Comparison between 8 patients who developed HCC and 551 who remained tumor-free during surveillance
Features . | Patients who developed HCC, n = 8 . | Patients who did not develop HCC, n = 551 . | P . |
---|---|---|---|
Hemophilia A (%) | 6 (75) | 452 (82) | 2 |
Hemophilia B (%) | 2 (25) | 57 (10) | NS |
Other coagulopathies (%) | 0 | 42 (8) | NA |
Age, y (range) | 56 (51-69)* | 39 (14-88)† | < .001 |
Age at infection, y (range) | 33 (18-55) | 9 (0-62) | < .001 |
Duration of infection, y (range) | 21 (13-36) | 26 (14-65) | NS |
Cirrhosis (%) | 8 (100) | 58 (11) | < .001 |
Alcohol intake, more than 80 g/d (%) | 3 (37) | 35 (6) | < .05 |
AFP level at entry, ng/mL (range) | 6 (3-26) | 2 (0.1-82) | < .005 |
ALT level at entry, IU/L (range) | 127 (53-206) | 65 (5-645) | < .05 |
HBV infected (%) | 1 (12) | 26 (5) | NS |
HIV infected (%) | 1 (12) | 126 (23) | NS |
Interferon treatment (%) | 0 | 121 (22) | NS |
Features . | Patients who developed HCC, n = 8 . | Patients who did not develop HCC, n = 551 . | P . |
---|---|---|---|
Hemophilia A (%) | 6 (75) | 452 (82) | 2 |
Hemophilia B (%) | 2 (25) | 57 (10) | NS |
Other coagulopathies (%) | 0 | 42 (8) | NA |
Age, y (range) | 56 (51-69)* | 39 (14-88)† | < .001 |
Age at infection, y (range) | 33 (18-55) | 9 (0-62) | < .001 |
Duration of infection, y (range) | 21 (13-36) | 26 (14-65) | NS |
Cirrhosis (%) | 8 (100) | 58 (11) | < .001 |
Alcohol intake, more than 80 g/d (%) | 3 (37) | 35 (6) | < .05 |
AFP level at entry, ng/mL (range) | 6 (3-26) | 2 (0.1-82) | < .005 |
ALT level at entry, IU/L (range) | 127 (53-206) | 65 (5-645) | < .05 |
HBV infected (%) | 1 (12) | 26 (5) | NS |
HIV infected (%) | 1 (12) | 126 (23) | NS |
Interferon treatment (%) | 0 | 121 (22) | NS |